{
"id":"mk19_b_rm_s10",
"subspecialtyId":"rm",
"title":"Systemic Sclerosis",
"jsonContent":{
"type":"section",
"id":"mk19_b_rm_s10",
"title":{
"__html":"Systemic Sclerosis"
},
"titleNode":{
"type":"section-title",
"hlId":"a5aba2",
"children":[
"Systemic Sclerosis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s10_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"bdaa4f",
"children":[
"Systemic sclerosis (SSc) is a multiorgan disease characterized by fibrosis and vasculopathy. The skin is the most apparent target, but internal organs are also affected. SSc is relatively rare, with a prevalence of 275 cases per million and an annual incidence of 19 cases per million. The peak incidence occurs in patients age 20 to 50 years. It is more common among women and Black persons."
]
},
{
"type":"p",
"hlId":"e76ec7",
"children":[
"Vascular injury, vascular and visceral fibrosis, and innate and adaptive immune activation with autoantibody production play interactive roles in SSc. Genome-wide association studies have identified up to 28 risk loci for SSc and underlined the importance of natural killer cell activity in SSc. One of the earliest SSc manifestations is Raynaud phenomenon, suggesting that vascular injury precedes the fibrotic reaction. With vascular damage, the endothelial cells release endothelin-1, a potent vasoconstrictor that also induces vascular smooth muscle proliferation and fibroblast activation. Platelet activation occurs concurrently with subsequent release of growth factors that promote further vasoconstriction, fibroblast activation, and collagen production. B cells are also activated and produce interleukin-6, which further stimulates fibroblasts and leads to autoantibody production. These and other processes cause increased collagen production and deposition by activated scleroderma fibroblasts, along with progressive obliterative vasculopathy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_2",
"title":{
"__html":"Classification"
},
"titleNode":{
"type":"section-title",
"hlId":"5c9335",
"children":[
"Classification"
]
},
"children":[
{
"type":"p",
"hlId":"d3304a",
"children":[
"The 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc provide a rigorous definition of SSc that is not formally intended for diagnosis and may be too restrictive in clinical practice. However, they can provide useful guidance when a patient presents with features suggesting SSc ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t28",
"wrapId":"1",
"children":[
"Table 28"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_rm_t28"
]
},
{
"type":"p",
"hlId":"0e5d94",
"children":[
"SSc is divided into three subtypes based on the extent of skin involvement: limited cutaneous systemic sclerosis (LcSSc), diffuse cutaneous systemic sclerosis (DcSSc), and systemic sclerosis sine scleroderma (internal organ involvement only). Specific long-term complications may be more likely in one subtype than another; however, overlap is common. LcSSc, formerly known as the CREST syndrome, is less commonly accompanied by fibrosis of internal organs than is DcSSc but is more commonly associated with pulmonary arterial hypertension. Patients with LcSSc have manifestations that can include calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST); all five conditions may not be present."
]
},
{
"type":"p",
"hlId":"a3b2bc",
"children":[
"Various disorders may present with skin thickening and other manifestations that overlap with SSc findings; these conditions should be considered in the differential diagnosis of SSc ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t29",
"wrapId":"2",
"children":[
"Table 29"
]
}
]
},
")"
]
},
". These conditions are not typically associated with Raynaud phenomenon, and the absence of Raynaud phenomenon in a patient with skin thickening makes SSc unlikely."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_rm_t29"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"70bae2",
"children":[
"Systemic sclerosis is a multiorgan disease characterized by fibrosis and vasculopathy; the skin is the principal target, and Raynaud phenomenon is one of the earliest manifestations."
]
},
{
"type":"keypoint",
"hlId":"a08330",
"children":[
"Systemic sclerosis is divided into three subtypes based on the extent of skin involvement: limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma."
]
},
{
"type":"keypoint",
"hlId":"f580d7",
"children":[
"The absence of Raynaud phenomenon in a patient with skin thickening makes systemic sclerosis unlikely."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"05bef4",
"children":[
"The diagnosis of SSc depends on the presence of specific clinical findings and autoantibodies, which are present in 90% to 95% of patients ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t30",
"wrapId":"3",
"children":[
"Table 30"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_rm_t30"
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_1",
"title":{
"__html":"Cutaneous Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"b93748",
"children":[
"Cutaneous Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"e217df",
"children":[
"The skin is the organ most commonly involved in SSc, with the hands being universally affected. In LcSSc, the skin over the fingers/hands, face, and neck is typically affected. In DcSSc, skin involvement is more extensive and additionally includes the upper arms, trunk, and lower extremities."
]
},
{
"type":"p",
"hlId":"41d741",
"children":[
"The earliest skin manifestations in DcSSc are often diffusely swollen fingers/hands. This will later give way to thickened, bound-down, atrophic skin. Skin thickening in LcSSc may be more subtle than in DcSSc, and the inability to tent the skin over the fingers (sclerodactyly) may be an important clue. The skin changes can lead to joint contractures ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f39",
"wrapId":"4",
"children":[
"Figure 39"
]
}
]
},
")"
]
},
". Small mat-like telangiectasias are common in LcSSc and occasionally occur in DcSSc. They are found on the hands and face and can also be seen on the oral mucosal side of the lips. They blanch with light pressure. Poikiloderma can occur in areas of fibrosis and consists of areas of hyperpigmentation mixed with hypopigmentation that give the skin a salt-and-pepper appearance. Facial skin involvement can lead to limitation of the oral aperture and difficulty eating. In addition, the face is typically devoid of wrinkles."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_rm_f39"
]
},
{
"type":"p",
"hlId":"1b0bb4",
"children":[
"Calcinosis occurs in approximately 25% of patients with SSc, typically in the hands, forearms, elbows, gluteal region, and iliac crest ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f40",
"wrapId":"5",
"children":[
"Figure 40"
]
}
]
},
")"
]
},
". These deposits can be seen or felt and are easily detected on radiographs."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_rm_f40"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_2",
"title":{
"__html":"Musculoskeletal Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"7bc1e8",
"children":[
"Musculoskeletal Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"1a797f",
"children":[
"Joint involvement occurs in 12% to 65% of patients with SSc; it is mainly polyarticular and can be erosive, with hand/wrist predominance. SSc is one of the few forms of inflammatory arthritis that affects the distal interphalangeal joints. Between 1% and 5% of patients have a rheumatoid arthritis–SSc overlap, with positivity for anti–cyclic citrullinated antibodies and classic rheumatoid arthritis manifestations along with those of SSc."
]
},
{
"type":"p",
"hlId":"ad150d",
"children":[
"Patients with SSc may develop acro-osteolysis, or resorption of the terminal bony tuft of the fingers and, less commonly, the toes; the prevalence is as high as 20% to 40% in more severe disease ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f41",
"wrapId":"6",
"children":[
"Figure 41"
]
}
]
},
")"
]
},
". This manifestation is typically seen in patients with significant distal vascular involvement, including ulceration, ischemia, and calcinosis."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_rm_f41"
]
},
{
"type":"p",
"hlId":"df1fc6",
"children":[
"Tendon rubs can be felt or heard with a stethoscope because fibrosis affects tendons or tendon sheaths. These occur in about 10% of patients with DcSSc."
]
},
{
"type":"p",
"hlId":"9601ee",
"children":[
"SSc-associated myositis occurs in 10% to 15% of patients. Myalgia and proximal muscle weakness are common symptoms. Serum creatine kinase and/or serum aldolase levels are elevated, and electromyogram demonstrates myopathic changes. There is a strong association between SSc-associated myositis and myocardial involvement. The presence of anti–PM-Scl antibodies identifies patients with an overlap between polymyositis and SSc. These patients usually have less skin and gastrointestinal involvement but have more calcinosis and lung disease."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_3",
"title":{
"__html":"Vascular Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"86474c",
"children":[
"Vascular Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"6b50b4",
"children":[
"Raynaud phenomenon occurs in approximately 95% of patients with SSc; it is the most common early manifestation of SSc, typically occurring years before recognizable SSc. Raynaud phenomenon is initially episodic, but with vascular fibrosis, the blood supply becomes permanently restricted. SSc will develop in approximately 80% of patients with the combination of Raynaud phenomenon, an SSc-associated autoantibody, and nailfold capillary changes in an SSc pattern ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f42",
"wrapId":"7",
"children":[
"Figure 42"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_rm_f42"
]
},
{
"type":"p",
"hlId":"c8869f",
"children":[
"Digital ulcers occur in about 15% of patients with SSc, typically on the extensor surfaces and tips of the fingers ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f43",
"wrapId":"8",
"children":[
"Figure 43"
]
}
]
},
")"
]
},
" and toes but also on the dorsum of hands and feet and even on the lower extremities. Vascular changes in the extremities may indicate similar involvement of internal organs."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_rm_f43"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_4",
"title":{
"__html":"Cardiac Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"ee07f2",
"children":[
"Cardiac Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"e727f5",
"children":[
"Myocardial fibrosis is a consequence of microvascular disease and a cause of early death. It results from repetitive ischemia-reperfusion injury of the myocardium. Myocardial involvement may lead to heart failure, intraventricular conduction block, and arrhythmias. Diastolic dysfunction is more common than systolic dysfunction, and a right bundle branch block is a predictor of early mortality in SSc."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_5",
"title":{
"__html":"Gastrointestinal Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"210365",
"children":[
"Gastrointestinal Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"6a9d41",
"children":[
"Symptoms of esophageal dysmotility and reflux are common in all forms of SSc and may offer an early clue to the diagnosis when associated with other symptoms."
]
},
{
"type":"p",
"hlId":"c5a5d5",
"children":[
"Approximately 80% of patients with SSc have involvement of the lower two thirds (smooth muscle portion) of the esophagus, manifesting primarily as symptoms of dysmotility and/or gastroesophageal reflux disease. Esophageal involvement is associated with an increased risk for Barrett esophagus and adenocarcinoma. A dilated esophagus on chest imaging is a clue to esophageal involvement."
]
},
{
"type":"p",
"hlId":"8d932c",
"children":[
"Gastric symptoms also result mainly from dysmotility. Patients describe early satiety and may report nausea and vomiting as a result of delayed gastric emptying. Gastric antral vascular ectasia is most common in patients with DcSSc and those with anti-RNA polymerase III antibodies. Bleeding ectasias can cause significant blood loss."
]
},
{
"type":"p",
"hlId":"0ab7cc",
"children":[
"Small intestinal bacterial overgrowth is common and can cause malabsorption and diarrhea. The diarrhea is described as explosive and typically follows a meal. Diagnosis is established by a hydrogen breath test, although an empiric trial of rotating antibiotics is often used. Small intestine dysmotility can result in pseudo-obstruction. Large intestine dysmotility may lead to constipation, and vascular ectasia can occur in the large intestine. Some patients may develop fecal incontinence."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_6",
"title":{
"__html":"Kidney Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"299cfa",
"children":[
"Kidney Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"8e92de",
"children":[
"Scleroderma renal crisis affects 5% of patients with DcSSc and 2% of patients with LcSSc. Scleroderma renal crisis was previously the chief cause of death in SSc. Risk factors for scleroderma renal crisis include DcSSc, use of glucocorticoids (>7.5 mg/d), and the presence of anti-RNA polymerase III antibodies. The more recent lower incidence of scleroderma renal crisis is ascribed to the avoidance of glucocorticoids in SSc and the use of calcium channel blockers, which are renal protective, to treat Raynaud phenomenon."
]
},
{
"type":"p",
"hlId":"086a8b",
"children":[
"Scleroderma renal crisis occurs within 4 years of SSc onset in 75% of cases. Patients characteristically present with manifestations of hypertensive emergency, including headache, encephalopathy, seizures, and hypertensive retinopathy. Rarely, a normotensive form of scleroderma renal crisis can occur. Risk factors for a poor prognosis include male sex, older age, and heart failure. Changes in blood pressure from ambulatory baseline measurements may alert physicians to an impending renal crisis."
]
},
{
"type":"p",
"hlId":"58b870",
"children":[
"Laboratory findings include microangiopathic hemolytic anemia, thrombocytopenia, and proteinuria. The serum creatinine level is typically elevated and may remain so for some time after blood pressure is controlled. Abnormalities in the renin-angiotensin-aldosterone system and in endothelin-1 are thought to contribute to the pathophysiology. Although ACE inhibitors have dramatically improved the outcome of patients with scleroderma renal crisis, prophylactic use of ACE inhibitors may actually worsen scleroderma renal crisis outcomes and is not recommended even in high-risk patients."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_3_7",
"title":{
"__html":"Lung Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"585d83",
"children":[
"Lung Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"1eb277",
"children":[
"Lung involvement in SSc includes pleuritis and pleural effusions, interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), bronchiolitis, pulmonary veno-occlusive disease, respiratory muscle weakness, and skin involvement of the trunk that restricts chest wall movement. Patients are also at increased risk for lung cancer."
]
},
{
"type":"p",
"hlId":"c8ba4a",
"children":[
"Significant ILD occurs in 50% of patients with DcSSc (85% of patients with anti–Scl-70 antibodies) and 35% of patients with LcSSc and is the main cause of disease-associated death. In patients with SSc, men are more likely than women to develop ILD, and Black persons tend to have more severe disease than other ethnic groups. The most common high-resolution CT pattern is nonspecific interstitial pneumonitis followed by usual interstitial pneumonitis. An abnormal FVC early in the disease course (within the first 5 years) is highly predictive of the development of more severe disease, as is fibrosis of more than 20% of lung volume on baseline high-resolution CT. There is a strong association between ILD and gastroesophageal reflux disease, but whether the latter contributes to ILD (through aspiration) is uncertain. All patients should undergo pulmonary function testing and high-resolution CT at the time of initial SSc diagnosis, and pulmonary function testing with D",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"LCO"
]
},
" should be repeated every 6 to 12 months for 5 years. A 10% decline in FVC or 15% decline in D",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"LCO"
]
},
" within 12 months should raise concern for progression."
]
},
{
"type":"p",
"hlId":"7e9a10",
"children":[
"PAH has a prevalence of 10% in SSc. Patients with PAH present with exertional dyspnea. With more advanced disease, they may have chest pain and lower extremity edema. Patients with SSc should undergo echocardiography annually, and for new or concerning symptoms. Pulmonary function testing can provide a clue to underlying PAH; an FVC/D",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"LCO"
]
},
" ratio of 1.6 or greater suggests the diagnosis. See ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s6_2",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
" for further discussion of diagnosis and treatment."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"aa5c72",
"children":[
"Raynaud phenomenon is the most common early manifestation of systemic sclerosis."
]
},
{
"type":"keypoint",
"hlId":"c60c16",
"children":[
"The earliest skin manifestations of systemic sclerosis are often diffusely swollen fingers/hands; with time, the skin becomes thickened, atrophic, and immobile."
]
},
{
"type":"keypoint",
"hlId":"0a93d1",
"children":[
"Symptoms of esophageal dysmotility and reflux are common in all forms of systemic sclerosis and may offer an early clue to the diagnosis when associated with other symptoms."
]
},
{
"type":"keypoint",
"hlId":"d9ab75",
"children":[
"Patients with scleroderma renal crisis characteristically present with manifestations of hypertensive emergency."
]
},
{
"type":"keypoint",
"hlId":"3d6cc9",
"children":[
"Lung involvement in systemic sclerosis includes pulmonary arterial hypertension and interstitial lung disease (ILD); ILD is the main cause of disease-associated mortality."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_4",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"f9aeca",
"children":[
"Treatment options for systemic sclerosis are mainly symptomatic and organ system specific. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t31",
"wrapId":"9",
"children":[
"Table 31"
]
}
]
},
" outlines treatment options for manifestations of SSc."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_rm_t31"
]
},
{
"type":"p",
"hlId":"974b26",
"children":[
"ACE inhibitors (typically captopril) can be lifesaving in patients with scleroderma renal crisis and should be titrated to control blood pressure. Dialysis may be needed temporarily for scleroderma renal crisis. ACE inhibitor therapy should be continued in scleroderma renal crisis even in the presence of a rising serum creatinine level and the need for dialysis because late improvement may occur. The addition of plasma exchange to ACE inhibitors in patients with scleroderma renal crisis and microangiopathic features has been suggested; angiotensin receptor blockers should be considered only when ACE inhibitors are not tolerated."
]
},
{
"type":"p",
"hlId":"4ad012",
"children":[
"The Scleroderma Lung Study II compared cyclophosphamide for 1 year versus mycophenolate mofetil over 2 years for ILD in SSc. With both agents, FVC improved in approximately 75% to 80% and FVC worsened in 20% to 25% of patients. In 70% of patients in each group (especially those with DcSSc), skin scores improved significantly. Mycophenolate was better tolerated and has become a mainstay of therapy in these patients."
]
},
{
"type":"p",
"hlId":"51279f",
"children":[
"Nintedanib (a tyrosine kinase inhibitor) significantly slowed the decline in lung function among patients with ILD associated with SSc but did not affect other disease manifestations. The combination of nintedanib plus mycophenolate resulted in the slowest rate of decline in FVC per year."
]
},
{
"type":"p",
"hlId":"a38953",
"children":[
"Rituximab is a promising agent in SSc. In a controlled trial comparing rituximab versus cyclophosphamide for ILD associated with SSc, rituximab improved FVC and skin score to a greater degree than did cyclophosphamide. Autologous hematopoietic stem cell transplantation has been studied for several years in patients with rapidly progressive, severe SSc; one third to one half of patients had significant improvement in lung function, skin thickening, and antibody status. However, cost and potential toxicity limit the utility of stem cell transplantation."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7fb4f9",
"children":[
"Treatment options for systemic sclerosis are mainly symptomatic and organ system specific."
]
},
{
"type":"keypoint",
"hlId":"a8d8bd",
"children":[
"ACE inhibitors can be lifesaving in patients with scleroderma renal crisis and should be titrated to control blood pressure even in the presence of rising serum creatinine."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_5",
"title":{
"__html":"Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"0b1e9b",
"children":[
"Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"563455",
"children":[
"Pregnant patients with SSc may experience hypertensive disease, preeclampsia, preterm delivery, and low birth weight. A meta-analysis of pregnancies in patients with SSc suggested that although disease manifestations, including digital ulcers, may improve, 14% of patients may develop new manifestations or worsening of current disease during pregnancy; in another 10%, disease will worsen in the first 6 months postpartum. Contraindications to pregnancy in patients with SSc include PAH and severe restrictive lung disease (FVC <1 L)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"cd47c7",
"children":[
"Pregnant patients with systemic sclerosis may experience hypertensive disease, preeclampsia, preterm delivery, and low birth weight."
]
},
{
"type":"keypoint",
"hlId":"60b3d0",
"children":[
"Contraindications to pregnancy in patients with systemic sclerosis include pulmonary arterial hypertension and severe restrictive lung disease."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s10_6",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Blagojevic J, AlOdhaibi KA, Aly AM, et al. Pregnancy in systemic sclerosis: results of a systematic review and metaanalysis. J Rheumatol. 2020;47:881-887. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31474594",
"target":"_blank"
},
"children":[
"PMID: 31474594"
]
},
" doi:10.3899/jrheum.181460"
]
},
{
"type":"reference",
"children":[
"Distler O, Highland KB, Gahlemann M, et al; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-2528. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31112379",
"target":"_blank"
},
"children":[
"PMID: 31112379"
]
},
" doi:10.1056/NEJMoa1903076"
]
},
{
"type":"reference",
"children":[
"Hung G, Mercurio V, Hsu S, et al. Progress in understanding, diagnosing, and managing cardiac complications of systemic sclerosis. Curr Rheumatol Rep. 2019;21:68. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31813082",
"target":"_blank"
},
"children":[
"PMID: 31813082"
]
},
" doi:10.1007/s11926-019-0867-0"
]
},
{
"type":"reference",
"children":[
"McMahan ZH. Gastrointestinal involvement in systemic sclerosis: an update. Curr Opin Rheumatol. 2019;31:561-568. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31389815",
"target":"_blank"
},
"children":[
"PMID: 31389815"
]
},
" doi:10.1097/BOR.0000000000000645"
]
},
{
"type":"reference",
"children":[
"Namas R, Tashkin DP, Furst DE, et al; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res (Hoboken). 2018;70:439-444. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28544580",
"target":"_blank"
},
"children":[
"PMID: 28544580"
]
},
" doi:10.1002/acr.23282"
]
},
{
"type":"reference",
"children":[
"Sandler RD, Matucci-Cerinic M, Hughes M. Musculoskeletal hand involvement in systemic sclerosis. Semin Arthritis Rheum. 2020;50:329-334. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31812353",
"target":"_blank"
},
"children":[
"PMID: 31812353"
]
},
" doi:10.1016/j.semarthrit.2019.11.003"
]
},
{
"type":"reference",
"children":[
"Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57:2106-2113. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30053212",
"target":"_blank"
},
"children":[
"PMID: 30053212"
]
},
" doi:10.1093/rheumatology/key213"
]
},
{
"type":"reference",
"children":[
"Tashkin DP, Roth MD, Clements PJ, et al; Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-719. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27469583",
"target":"_blank"
},
"children":[
"PMID: 27469583"
]
},
" doi:10.1016/S2213-2600(16)30152-7"
]
},
{
"type":"reference",
"children":[
"Valenzuela A, Song P, Chung L. Calcinosis in scleroderma. Curr Opin Rheumatol. 2018;30:554-561. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30124603",
"target":"_blank"
},
"children":[
"PMID: 30124603"
]
},
" doi:10.1097/BOR.0000000000000539"
]
},
{
"type":"reference",
"children":[
"Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev. 2018;17:882-889. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30005860",
"target":"_blank"
},
"children":[
"PMID: 30005860"
]
},
" doi:10.1016/j.autrev.2018.03.012"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_rm_t28":{
"id":"mk19_b_rm_t28",
"number":28,
"bookId":"rm",
"title":{
"__html":"American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0f37f8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 28. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t28"
}
]
},
"American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b0cdd",
"class":"col hd l",
"children":[
"Manifestation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"221927",
"class":"col hd l",
"children":[
"Additional Manifestations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3fd8d",
"class":"col hd l",
"children":[
"Weight/Score",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4bdfea",
"class":"cell txt l",
"children":[
"Skin thickening of fingers of both hands extending proximal to the MCPs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"45c48c",
"class":"cell txt l",
"children":[
"9"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35a560",
"class":"cell txt l",
"children":[
"Skin thickening of the fingers (count higher score only)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c3ba9",
"class":"cell txt l",
"children":[
"Puffy fingers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d17177",
"class":"cell txt l",
"children":[
"Sclerodactyly of fingers distal to the MCPs but proximal to PIPs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a87ff6",
"class":"cell txt l",
"children":[
"4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d31b3",
"class":"cell txt l",
"children":[
"Fingertip lesions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b65b8",
"class":"cell txt l",
"children":[
"Digital tip ulcers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"284608",
"class":"cell txt l",
"children":[
"Fingertip pitting scars"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e43a9",
"class":"cell txt l",
"children":[
"Telangiectasia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a61479",
"class":"cell txt l",
"children":[
"Abnormal nailfold capillaries"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1df63a",
"class":"cell txt l",
"children":[
"Pulmonary hypertension and/or interstitial lung disease (maximum score is 2)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f361bb",
"class":"cell txt l",
"children":[
"Pulmonary hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33ef80",
"class":"cell txt l",
"children":[
"Interstitial lung disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3e3de",
"class":"cell txt l",
"children":[
"Raynaud phenomenon"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da1945",
"class":"cell txt l",
"children":[
"SSc-related autoantibodies (maximum score is 3)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b87a03",
"class":"cell txt l",
"children":[
"Anticentromere"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57d20d",
"class":"cell txt l",
"children":[
"Anti–Scl-70 (antitopoisomerase-1)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de2a4f",
"class":"cell txt l",
"children":[
"Anti-RNA polymerase III"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"MCP = metacarpophalangeal; PIP = proximal interphalangeal; SSc = systemic sclerosis."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"The total score is determined by adding the maximum weight (score) in each category. A score of 9 or more equates to definite systemic sclerosis."
],
[
"From van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 2013;72:1747-55. doi:10.1136/annrheumdis-2013-204424. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24092682",
"target":"_blank"
},
"children":[
"PMID: 24092682"
]
},
" Copyright 2013, American College of Rheumatology. Adapted with permission from BMJ Publishing Group Ltd."
]
]
},
"mk19_b_rm_t29":{
"id":"mk19_b_rm_t29",
"number":29,
"bookId":"rm",
"title":{
"__html":"Common Manifestations/Features of Scleroderma Spectrum Disorders"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"606e4d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 29. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t29"
}
]
},
"Common Manifestations/Features of Scleroderma Spectrum Disorders"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"589189",
"class":"col hd l",
"children":[
"Disorder"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"baaf97",
"class":"col hd l",
"children":[
"Manifestation/Feature"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"a5aba2",
"class":"col hd l",
"children":[
"Systemic Sclerosis"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40404a",
"class":"cell txt l",
"children":[
"Diffuse cutaneous systemic sclerosis (DcSSc)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d9d03",
"class":"cell txt l",
"children":[
"Distal and proximal skin thickening (face, chest, abdomen; proximal to elbows and knees); commonly has visceral organ involvement"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6d5e4",
"class":"cell txt l",
"children":[
"Skin involvement is extensive and is commonly accompanied by internal organ fibrosis and ILD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96ede5",
"class":"cell txt l",
"children":[
"Limited cutaneous systemic sclerosis (LcSSc)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98e742",
"class":"cell txt l",
"children":[
"Distal (face, neck, hands, feet), but not proximal, skin thickening; typically not accompanied by internal organ fibrosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42184d",
"class":"cell txt l",
"children":[
"More likely to develop PAH and Raynaud phenomenon early in the disease and frequently develop calcinosis cutis, telangiectasia, and esophageal dysmotility"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d261de",
"class":"cell txt l",
"children":[
"Systemic sclerosis sine scleroderma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1089d",
"class":"cell txt l",
"children":[
"Fibrosing organ involvement without skin thickening"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5a549a",
"class":"cell txt l",
"children":[
"Difficult to diagnose; prognosis may be similar to LcSSc"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"e88d42",
"class":"col hd l",
"children":[
"Localized Scleroderma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"24ae9b",
"class":"cell txt l",
"children":[
"Morphea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7386c6",
"class":"cell txt l",
"children":[
"Focal plaques of skin thickening, generally on the trunk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c770d1",
"class":"cell txt l",
"children":[
"Systemic manifestations or Raynaud phenomenon is extremely rare"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3cbfae",
"class":"cell txt l",
"children":[
"Linear scleroderma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"148194",
"class":"cell txt l",
"children":[
"Streaks/lines of thickened skin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c4466",
"class":"cell txt l",
"children":[
"Same as morphea"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"be6c52",
"class":"col hd l",
"children":[
"Scleroderma-like Conditions",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21dea0",
"class":"cell txt l",
"children":[
"Eosinophilic fasciitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ad90b",
"class":"cell txt l",
"children":[
"Orange peel induration (peau d’orange) of proximal extremities with sparing of hands and face; peripheral eosinophilia; skin retraction over the superficial veins may be more apparent with elevation of an affected limb"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2b4e0",
"class":"cell txt l",
"children":[
"Full-thickness skin biopsy demonstrates lymphocytes, plasma cells, and eosinophils infiltrating the deep fascia; glucocorticoids are mainstay of treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"233eef",
"class":"cell txt l",
"children":[
"Nephrogenic systemic fibrosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3e390",
"class":"cell txt l",
"children":[
"Secondary to gadolinium in patients with kidney disease; brawny, wood-like induration of extremities, sparing the digits"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"269ce4",
"class":"cell txt l",
"children":[
"Skeletal muscle fibrosis with contractures and/or cardiac muscle involvement can occur, with cardiomyopathy and increased mortality; changes in use and formulation of gadolinium have reduced incidence"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5567b7",
"class":"cell txt l",
"children":[
"Scleredema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb86bc",
"class":"cell txt l",
"children":[
"Indurated plaques/patches on back, shoulder girdle, and neck"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db4706",
"class":"cell txt l",
"children":[
"Typically seen in long-standing diabetes mellitus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e3036",
"class":"cell txt l",
"children":[
"Scleromyxedema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"949f63",
"class":"cell txt l",
"children":[
"Waxy, yellow-red papules over thickened skin of face, upper trunk, neck, and arms; deposition of mucin with large numbers of stellate fibroblasts in the dermis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba4924",
"class":"cell txt l",
"children":[
"Associated with paraproteinemia (IgGλ) and may therefore occur in the setting of multiple myeloma or AL amyloidosis; more frequent in men"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5cebf",
"class":"cell txt l",
"children":[
"Chronic graft-versus-host disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"295c98",
"class":"cell txt l",
"children":[
"Lichen planus–like skin lesions, or localized or generalized skin thickening"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09ba5b",
"class":"cell txt l",
"children":[
"Occurs most commonly after hematopoietic stem cell transplantation; may occasionally be seen after blood transfusion in immunocompromised host"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52c3ef",
"class":"cell txt l",
"children":[
"Drug and toxin exposure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31abf0",
"class":"cell txt l",
"children":[
"Can produce scleroderma-like tissue changes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc7ed4",
"class":"cell txt l",
"children":[
"Examples: bleomycin, docetaxel, pentazocine, L-tryptophan, organic solvents"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ILD = interstitial lung disease; PAH = pulmonary arterial hypertension."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Scleroderma-like skin changes may also be a manifestation of systemic endocrine, kidney, or infiltrative disorders."
]
]
},
"mk19_b_rm_t30":{
"id":"mk19_b_rm_t30",
"number":30,
"bookId":"rm",
"title":{
"__html":"Autoantibodies and Their Associations in Systemic Sclerosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2bcbd8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 30. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t30"
}
]
},
"Autoantibodies and Their Associations in Systemic Sclerosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b08bac",
"class":"col hd l",
"children":[
"Autoantibody"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c9833a",
"class":"col hd l",
"children":[
"Main Clinical Associations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b534b1",
"class":"cell txt l",
"children":[
"Antinuclear antibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ed9fa",
"class":"cell txt l",
"children":[
"DcSSc; LcSSc"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51f54b",
"class":"cell txt l",
"children":[
"Overall prevalence in SSc, 70%; not associated with specific manifestations"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b17a0c",
"class":"cell txt l",
"children":[
"Anticentromere (kinetochore proteins)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c9bf7a",
"class":"cell txt l",
"children":[
"LcSSc with or without PAH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c44643",
"class":"cell txt l",
"children":[
"Overall prevalence in SSc, ≤30%; highly associated (>90%) with LcSSc"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4bae6",
"class":"cell txt l",
"children":[
"Anti–Scl-70 (DNA topoisomerase-1)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd7ffb",
"class":"cell txt l",
"children":[
"DcSSc; ILD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"139232",
"class":"cell txt l",
"children":[
"Overall prevalence in SSc, ≤30%; highly associated with DcSSc"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5fb05",
"class":"cell txt l",
"children":[
"Anti–RNA polymerase III"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eac376",
"class":"cell txt l",
"children":[
"DcSSc; scleroderma renal crisis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9684b7",
"class":"cell txt l",
"children":[
"Useful in DcSSc with negativity for anti–Scl-70"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0033c3",
"class":"cell txt l",
"children":[
"Anti–U3-RNP (fibrillarin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"725c60",
"class":"cell txt l",
"children":[
"DcSSc; PAH; myositis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebf1b3",
"class":"cell txt l",
"children":[
"Associated with poor outcome; more common in Black men"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3d011",
"class":"cell txt l",
"children":[
"Anti–PM-Scl"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b205c",
"class":"cell txt l",
"children":[
"Myositis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0341d0",
"class":"cell txt l",
"children":[
"Associated with overlap syndrome and polymyositis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65eb79",
"class":"cell txt l",
"children":[
"Anti-Ku"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b205c",
"class":"cell txt l",
"children":[
"Myositis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2cc58",
"class":"cell txt l",
"children":[
"Rare"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"386228",
"class":"cell txt l",
"children":[
"Anti-Th/To"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b53491",
"class":"cell txt l",
"children":[
"LcSSc; PAH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2cc58",
"class":"cell txt l",
"children":[
"Rare"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DcSSc = diffuse cutaneous systemic sclerosis; ILD = interstitial lung disease; LcSSc = limited cutaneous systemic sclerosis; PAH = pulmonary arterial hypertension; RNP = ribonucleoprotein; SSc = systemic sclerosis."
]
]
},
"mk19_b_rm_t31":{
"id":"mk19_b_rm_t31",
"number":31,
"bookId":"rm",
"title":{
"__html":"Treatment Options for Common Manifestations of Systemic Sclerosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2c336a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 31. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t31"
}
]
},
"Treatment Options for Common Manifestations of Systemic Sclerosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c54e40",
"class":"col hd l",
"children":[
"Manifestations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6bcfe",
"class":"cell txt l",
"children":[
"Cutaneous manifestations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a61427",
"class":"cell txt l",
"children":[
"Methotrexate, mycophenolate, cyclophosphamide, and rituximab have been shown to improve skin scores."
]
},
" ",
{
"type":"p",
"hlId":"fabe9d",
"class":"cell txt l",
"children":[
"For pruritus, antihistamines can be tried; low-dose prednisone can also help but doses >7.5 mg/d should be used with caution because of risk for scleroderma renal crisis."
]
},
" ",
{
"type":"p",
"hlId":"b68057",
"class":"cell txt l",
"children":[
"Laser therapy can be used for telangiectasias."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5d1bc",
"class":"cell txt l",
"children":[
"Musculoskeletal manifestations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df7c84",
"class":"cell txt l",
"children":[
"NSAIDs, intra-articular or low-dose prednisone, hydroxychloroquine, or methotrexate can be used for arthralgia/arthritis."
]
},
" ",
{
"type":"p",
"hlId":"436fa8",
"class":"cell txt l",
"children":[
"Methotrexate, azathioprine, or mycophenolate can be used for significant myositis."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3e3de",
"class":"cell txt l",
"children":[
"Raynaud phenomenon"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e947a",
"class":"cell txt l",
"children":[
"Cold avoidance; gloves; central warmth"
]
},
" ",
{
"type":"p",
"hlId":"39fb9a",
"class":"cell txt l",
"children":[
"Calcium channel blockers; sildenafil; losartan; prazosin"
]
},
" ",
{
"type":"p",
"hlId":"ff3217",
"class":"cell txt l",
"children":[
"Topical nitrates; low-dose aspirin"
]
},
" ",
{
"type":"p",
"hlId":"d3ee2f",
"class":"cell txt l",
"children":[
"Digital sympathectomy for refractory cases"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d390f4",
"class":"cell txt l",
"children":[
"Gastroesophageal reflux disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53fc76",
"class":"cell txt l",
"children":[
"Avoid eating close to bedtime; head-of-bed elevation"
]
},
" ",
{
"type":"p",
"hlId":"8388c5",
"class":"cell txt l",
"children":[
"H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" blockers; proton pump inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"8b58b4",
"class":"cell txt l",
"children":[
"Surgical fundoplication"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d00eed",
"class":"cell txt l",
"children":[
"Gastrointestinal dysmotility"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"915f03",
"class":"cell txt l",
"children":[
"Metoclopramide (avoid long-term use); domperidone (investigational limited-access program), erythromycin; cisapride (investigational limited-access program)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"264a3b",
"class":"cell txt li",
"children":[
"Gastric antral vascular ectasia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b65e8",
"class":"cell txt l",
"children":[
"Ablation laser therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72b08f",
"class":"cell txt li",
"children":[
"Small intestine bacterial overgrowth"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df5591",
"class":"cell txt l",
"children":[
"Rotating antibiotics; if fat malabsorption, cholestyramine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6243e2",
"class":"cell txt li",
"children":[
"Pseudo-obstruction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d1596",
"class":"cell txt l",
"children":[
"Promotility agent such as domperidone can be tried; if resistant, octreotide may be useful."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5249f2",
"class":"cell txt li",
"children":[
"Constipation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"483dc3",
"class":"cell txt l",
"children":[
"Fiber; stool softeners; polyethylene glycol"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"899df7",
"class":"cell txt l",
"children":[
"Scleroderma renal crisis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84837b",
"class":"cell txt l",
"children":[
"ACE inhibitors (typically captopril), plasma exchange"
]
},
" ",
{
"type":"p",
"hlId":"836bcf",
"class":"cell txt l",
"children":[
"Dialysis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33ef80",
"class":"cell txt l",
"children":[
"Interstitial lung disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27e81d",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil; cyclophosphamide; nintedanib; rituximab; stem cell transplant in rapidly progressive cases"
]
},
" ",
{
"type":"p",
"hlId":"4cd1a1",
"class":"cell txt l",
"children":[
"Lung transplantation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4afff4",
"class":"cell txt l",
"children":[
"Pulmonary arterial hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3caca5",
"class":"cell txt l",
"children":[
"Supplemental oxygen; treat right-sided heart failure"
]
},
" ",
{
"type":"p",
"hlId":"f6889b",
"class":"cell txt l",
"children":[
"Calcium channel blockers (if positive response to vasoreactivity testing); prostanoids; endothelin receptor antagonists; phosphodiesterase-5 inhibitors; soluble guanylate cyclase stimulator"
]
},
" ",
{
"type":"p",
"hlId":"72f144",
"class":"cell txt l",
"children":[
"Combination therapy (ambrisentan and tadalafil); lung transplantation"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}